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Objectives: Discrete-Event-Simulation (DES) is a commonly used modeling 
tool to analyze the comparative effectiveness of alternative health technologies 
and to optimize resource allocation in health care settings. DES models are often 
rather complex and visualization is very important to improve transparency and 
acceptability. This study aims to illustrate and contrast alternative visualization 
techniques on a decision-analytic model for breast cancer. MethOds: DES visu-
alization methods and their applications in health care, engineering, and opera-
tions research were sought from a wide variety of sources, including literature 
databases (e.g., PubMed) and webpages of simulation conference (e.g., Winter 
Simulation Conference), academic societies etc. Based on this review, alternative 
visualization techniques for the conceptual model were selected, applied on a real 
world modeling example and compared. Results: In health care, the recently 
published ISPOR-SMDM Modeling Good Research Practice guidelines recommend 
flow diagrams or state charts to represent the key elements of a model, including 
the possible pathways, and the presence of queues and decision points. For flow 
charts, we found an international standard (ISO 5807). The application of standards 
like this could support harmonization of process-oriented models. In general, flow 
charts may lack the information of health states and transitions between health 
states that are relevant for clinicians to review the model. The semantic for state 
charts invented by Harel provides a further development of the bubble diagrams 
of State-Transition (Markov) Models (e.g. one state containing other states, one 
state detects changes in another). In state charts, health states could explicitly 
be named but treatment processes and resources use are less explicit. For DES 
software implementation, state charts seem to be less intuitive. For both methods, 
the application of visualization standards and guidelines was not always straight 
forward for our breast cancer model. cOnclusiOns: In the case example there 
was no superior visualization technique.
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Objectives: Most cancer care models are based on observed clinical events such 
as recurrence-free and overall survival. Times at which events are recorded depend 
not only on effectiveness of treatment, but also on timing of examinations and 
types of tests performed. Should these change, observation times would change 
as well. Construct a microsimulation model that describes the cancer disease 
process using a description of underlying tumor growth as well as its interaction 
with diagnostics, treatments and surveillance. The aim is to arrive at a frame-
work that allows for exploration of the impact of simultaneously altering two 
or more aspects of the care process. MethOds: The framework consists of two 
components; the disease model and the clinical management module. The disease 
model consists of atumor level, describing the growth and metastasis of the tumor, 
and a patient level, describing clinical observed states, such as recurrence and 
death, either from the disease or other causes. The clinical management module 
consists of the care patients receive, i.e. the diagnostic process, treatment and 
surveillance. This module interacts with the disease process, influencing the rate 
of transitioning between tumor growth states at the tumor level, and the rate of 
detecting a recurrence at the patient level. Results: A simulation study was 
performed to examine the feasibility of applying the framework to melanoma 
progression. Results demonstrated stage specific recurrence rates similar to those 
found in literature. cOnclusiOns: The proposed microsimulation model frame-
work allows for generating individual patient histories by simulating underlying 
tumor growth in interaction with clinical management. Our modeling approach 
allows for the exploration of the potential of drugs intervening in different parts 
of the tumor growth pathway. In addition, the approach allows for the evaluation 
of changing diagnostic patterns.
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Objectives: Economic evaluations typically include all costs relevant to a disease, 
not only drug-related costs. This is particularly relevant to oncology modelling, as 
costs are assigned to each health state in the model, and, therefore, extending sur-
vival also increases costs. Because patients often incur higher health care costs in 
the post-progressed state of disease where costs of disease management are high, 
extending survival and increasing a patient’s time in the post-progressed stage 
can be particularly costly. Empirical analyses of the implications of such methods 
have not yet been extensively investigated by assessing different scenarios such as 
baseline severity and prognosis. The objective of this research was to investigate 
the methodology used in oncology modelling, and to determine the effect that this 
has on predicted cost-effectiveness. MethOds: We developed a flexible three-state 
Zidovudine + Lamivudine combination therapy vs Zidovudine monotherapy, to 
treat HIV infection. Based on probabilistic simulations, cumulative incremental 
net monetary benefits (CINMB) at a CE threshold of £20,000/QALY and probabili-
ties of being cost-effective at various time-horizons (1-20 years) were estimated. 
Further, for each time-horizon, a CINMB frequency distribution was plotted and 
summary statistics were estimated. Results: For the combination therapy, while 
the outcome uncertainty increased over time, the decision uncertainty decreased. 
95% confidence interval for expected CINMB was narrowest at year 1 (-1,771£ to 
-1,755£) and widest at year 7 (2,101£ to 2,209£); simultaneously the probability of 
being cost effective increased from 5% to 80% during this time. Outcome uncer-
tainty, measured as the standard deviation of CINMB values stabilized after 5 
years while probability of the combination therapy being cost effective continued 
to increase, indicating that decision uncertainty does not vary in tandem with 
outcome uncertainty. cOnclusiOns: The above analysis shows that higher out-
come uncertainty does not necessarily lead to higher decision uncertainty. CINMB 
could be a useful tool to observe the relationships between outcome uncertainty, 
decision uncertainty and time.
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Objectives: To describe the practical approach implemented to construct a 
global cost-effectiveness model for T2DM therapies following a framework pro-
posed for the development of reference models to inform public funding deci-
sions. MethOds: 1) A systematic review of published models was conducted to 
conceptualise the model in terms of natural history and relevant effects to include. 
2) Clinical and health economic experts were selected to provide feedback during 
the model conceptualisation (to identify the appropriate modelling technique), the 
model implementation and the assessment of the results. 3) The model was built 
and populated based on the systematic identification of best available data, a net-
work meta-analyses, a review of previous T2DM submissions to health authorities 
and other published information. The model incorporated several structures for 
uncertain areas, such as: treatment patterns; type and timing of adverse events; 
their impact in the occurrence of long-term complications; and the impact of weight 
changes on relevant endpoints. 4) The model was then validated based on out-
puts’ accuracy, feedback from country affiliates and consistency with the CORE 
model results. 5) The critical feedback received by HTA bodies has also been used 
to refine the model and improve its credibility accordingly. Results: Experts’ input 
proved invaluable at each developmental stage. One challenge related to the com-
parability with other published T2DM models, which were not fully transparent 
regarding assumptions. This framework resulted in a flexible model, accurate and 
stable, and easily adaptable to different health care systems. Country adaptations 
have contributed to the identification of aspects that require relevant structural 
changes and their rationale. cOnclusiOns: The followed framework enhanced 
the transparency of the model and the accuracy of the results. Using a reference 
model across different countries, with adaptations made in consistency with this 
model, should help ensure consistent and comparable evaluations of the model 
across different countries.
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Objectives: Payers have a perception that orphan products are extremely 
expensive. The current health technology assessment (HTA) systems might be 
too restrictive for orphan drugs, therefore potentially denying patients access to 
life-saving medicines. While price is important, it should be considered in relation 
to a broader range of product attributes, such as unmet need and disease severity 
that are not considered in cost-effectiveness analysis used by many HTA agencies. 
To overcome these challenges multi-criteria decision analysis (MCDA) has been 
proposed as an alternative to evaluate technologies. The aim of this study was to 
identify criteria reported in the literature, and to assess their impact on the total 
“score” for each product in relation to price. MethOds: A systematic literature 
review was conducted to identify the most frequently cited attributes in MCDA. 
From the leading attributes identified, we reviewed and plotted the relationship 
between single attributes and the average annual treatment costs for several drugs 
used in the treatment of endocrine-related rare diseases. Annual treatment cost 
was based on UK prices for the average daily dose per patient. Results: The 
three most frequently mentioned attributes were ‘disease severity’, ‘treatment 
impact on condition’, and ‘level of research undertaken to support use of the prod-
uct’. Disease severity was not shown to influence product price. Similarly, orphan 
drugs are not necessarily more expensive than products without orphan drug 
status. There is little discernible relationship between treatment ‘convenience’ 
and average annual treatment cost. A trend was observed between the market size 
and the average annual treatment cost. cOnclusiOns: If society is concerned 
about equity and equal access to medicines for all patients, MCDA may offer a 
viable alternative to inform in reimbursement decisions for orphan drugs. The 
analysis can be used to inform investigations on the application of MCDAs in 
rare diseases.
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ment of AD and promising advances in health technologies have the potential to 
significantly impact on the burden of the disease. However, alongside treatment 
advances it is important to improve the evaluation framework if we are to capture 
the potential benefits to people with AD. Methods to model disease progression 
over time, for use in comparative and cost-effectiveness analyses (CEA), is a pri-
ority area for further research. The objective in this research is to develop a new 
framework for modeling AD progression over time using the three main symptom 
domains of cognitive function, behaviour and mood, and functioning. MethOds: 
Development of a descriptive system, comprising a set of health states for AD, using 
the three symptom domains. Statistical modeling of disease progression through 
states over time, using US data from the National Alzheimer’s Coordinating Center 
(NACC) (n= 3009). The model is tested in a decision-analytic context, using time to 
progression and a cost-per-QALY framework. Results: A 20-state disease progres-
sion pathway has been developed using multi-variate health states described using 
the three symptom domains. Transition probabilities and hazard rates have been 
estimated to model progression over time through the multi-variate descriptive 
system. In a baseline model over a 5-year timeframe, using mild-to-moderate AD 
starting states, 78% of people progressed to health states considered severe on at 
least one of the symptoms (46% severe for cognition). In a HTA context simulating a 
treatment with a modest effect the modeling framework predicted significant QALY 
differences between control and treatment over 5-years. cOnclusiOns: This new 
modeling framework shows promise and presents a broader opportunity to capture 
the impacts of treatment over time using a range of symptom domains.
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Objectives: The National Institute for Health and Care Excellence recommends 
utilising external data to evaluate the validity of extrapolation beyond trial follow-
up. The objective was to demonstrate the use of external data to guide long-term 
survival predictions where only short-term trial data are available. MethOds: 
Four-year patient-level data for chlorambucil and ofatumumab+chlorambucil from 
the COMPLEMENT-1 trial were available; the survival rate was over 70% at four 
years. Published 18-year Kaplan-Meier data for chlorambucil from the C9011 study, 
which compared fludarabine and chlorambucil, were used to simulate a patient-
level dataset. These data were not used directly as outcomes have improved sub-
stantially since patients were enrolled (1990-1994) and the chlorambucil dosing 
regimens differed. However the curve was used to guide the extrapolation of the 
COMPLEMENT-1 data using a three-stage approach: 1) Survival functions were fitted 
for the COMPLEMENT-1 and C9011 chlorambucil arms with an indicator for study. 
2) The average treatment effect (chlorambucil versus ofatumumab+chlorambucil) 
was estimated from survival analysis for both arms of COMPLEMENT-1 and 
the C9011 chlorambucil arm, with indicators for treatment and study. 3) For 
ofatumumab+chlorambucil, long-term survival was estimated by applying the 
treatment effect from stage 2 to the function for chlorambucil from stage 1. 
Exponential, gamma, Weibull, log-normal, log-logistic and Gompertz functions were 
fitted. Results: Weibull, Gompertz, and gamma functions provided reasonable fits 
during trial follow-up and plausible extrapolations (assessed by Akaike information 
criterion, Bayesian information criterion, graphical diagnostics, and expert clinical 
opinion). Survival predictions were markedly lower than conventional functions 
fitted to COMPLEMENT-1 data only (e.g. Weibull predictions for chlorambucil at 20 
years were 8% vs 26%, respectively). cOnclusiOns: Using long-term external data 
to guide the extrapolation provided plausible predictions for chlorambucil upon 
which alternative scenarios for the continuation of treatment effect observed in 
COMPLEMENT-1 could be explored.
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Objectives: Epidemiological projections sizing patient populations are fundamen-
tal to budget impact analyses and market forecasting. When disease risk evolves 
over time, as in the case of epidemiological transition, using historical estimates in 
epidemiological projection becomes unjustified. Incorporation of additional vari-
ables that model evolving risk may allow for more reliable forecasts. The hypothesis 
that gross domestic product per capita (GDP) is correlated with disease risk was 
tested for a variety of cancers using global epidemiological and economic data-
sets. MethOds: Age-standardized incidence for 18 cancer sites across 188 countries 
was retrieved from the International Agency for Research against Cancer for the 
years 1993-1997. Corresponding country-specific GDP data was collected from the 
World Bank. For each site, correlation between GDP and incidence was measured 
using R2and linear co-efficient values. Results: Risk is strongly correlated with 
GDP for all of the sites studied, with the exception of the stomach (R2= 0; p> 0.05). 
Correlation was strongest for those sites associated with diet/lifestyle factors 
prevalent in higher-income countries, namely: colorectal (R2= 0.61; p< 0.001), breast 
(R2= 0.61; p< 0.001) and lung (R2= 0.42; p< 0.001). Strong association was also seen for 
prostate (R2= 0.47; p< 0.001), although this may be explained by better case-detection 
in higher-income countries. Conversely, those cancer sites associated with infec-
tion showed a negative correlation, namely: cervix (R2= 0.33; p< 0.01), liver (R2= 0.09; 
p< 0.001) and oesophagus (R2= 0.06; p< 0.01). cOnclusiOns: GDP is strongly asso-
ciated with cancer risk and varies by organ site in a manner concordant with the 
evolving exposures to known pathogens that characterize epidemiological transi-
tion. On the assumption that such correlation is a marker for various causal relation-
ships, and that robust economic methods underlie GDP forecasts, it is reasonable to 
conclude that these correlations could be used to make epidemiological projections 
more accurate than projections assuming constant disease risk.
economic model with ten key parameters to calculate the ICERs associated with 
various combinations of inputs. Published HTAs were reviewed to determine the 
model inputs. Extensive scenario and multiway sensitivity analyses were carried 
out to document informative patterns and relationships between parameters that 
affected the results. Results: Results showed that cancer sub-types with higher 
post-progression costs reduced a treatments likelihood of being cost-effective. The 
results also highlighted specific thresholds at which various cancer-specific case 
studies or combinations of inputs, including drug price, resulted in the drug being 
deemed not cost-effective using a threshold of £20,000 per QALY. cOnclusiOns: 
The impact of post-progression costs can vary dependent on how these costs are 
modelled and also dependent on several factors, namely the ratios between health 
state utilities, ‘background’ costs, drug costs and the relative time spent in the 
stable and progressed disease states. It is demonstrated that, for many oncology 
treatments whose primary aim is to extend survival, this impact can be prohibitive 
to an intervention’s probability of being cost-effective.
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Objectives: Network Meta Analyses (NMAs) are often used to parameterise efficacy 
in decision models for economic evaluation. A common source of heterogeneity 
in NMA arises from the fact that treatments may be given at different doses. This 
variation may manifest as unexplained heterogeneity in standard NMA models and 
propagates through to the decision analysis. We aim to explore how dose-response 
NMA can be used to inform cost-effectiveness analysis using a cost-utility analysis 
of treatments for acute migraine. MethOds: We conducted four NMAs with differ-
ent assumptions around dose-response to inform an economic evaluation in acute 
migraine. Separate 1-level NMAs were conducted where interventions were ‘lumped’ 
at the ‘dose’, ‘treatment’ and ‘class’ levels and a multi-level NMA was conducted, 
assuming monotonic dose-response. All NMAs were used to inform effect sizes in 
an economic model; the model structure, costing methods and utility inputs from 
the NICE Headaches guideline were adopted. The NMA models were compared 
in terms of heterogeneity and Deviance Information Criteria (DIC). We report the 
results of the economic analyses using cost-effectiveness acceptability frontiers 
(CEAFs). Results: Dose-response parameterisation lead to NMA models with lower 
heterogeneity and better fit. Different dose-response parameterisations substan-
tially changed the resource allocation decision, particularly at lower willingness 
to pay thresholds. For the more complex NMA model, it is unclear from a decision 
making perspective which effect size estimates should be selected as inputs to 
the decision model and we show that careful consideration should be given to the 
relevance of individual doses and confounding bias. cOnclusiOns: Dose-response 
NMA provides a useful and arguably more appropriate method for conducting NMA 
for decision analysis. Careful consideration should be given to how to treat doses of 
the same intervention in NMA since different parameterisations may lead to biased 
effect sizes and sub-optimal conclusions around cost-effectiveness.
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Objectives: Majority of established pharmaceutical markets use pricing rules that 
reference products both across (international reference pricing; IRP) and within 
(therapeutic reference pricing; TRP) country-lines. Some markets, such as the UK, 
use no such rules and freely price therapies. IRP and TRP are used as effective 
measures to control price of pharmaceutical products. However, understanding the 
impact on a global level is considered highly complex, due to each market using 
different legislations and mechanisms. There is a growing need to better understand 
the impact of IRP and TRP on the decay of pharmaceutical drug prices and their 
effects on launch prices and sequencing across multiple markets. MethOds: We 
utilized a model to simulate the impact of IRP and TRP, as well as parallel trade, to 
quantitatively assess impact on drug prices across 40 markets (EU28, Switzerland, 
Russia, Iceland, Norway, Turkey, Israel, Brazil, Japan, South Korea, Australia, Canada 
and USA). The model uses simulating annealing parameters to also yield optimized 
launch sequences in all markets. Results: Outputs of the model include impact to 
volume, price and revenue as well as parallel trade. Using a dynamic launch map, 
the model provides optimized price and launch sequence of a given pharmaceutical 
product. Within a set window, the launch and reimbursement dates were optimized 
based on a divergent set of rules and country baskets, often differing from manu-
facturers expected launch prices and sequences. While manufacturers are often 
able to secure higher price for therapies in free-price markets, the model clearly 
demonstrates the spill-over impact of referencing (both formally and informally) 
across countries and within therapeutic groups. cOnclusiOns: Previously, launch 
sequences were optimized based on the implications on major markets. However, an 
expansive model looking at large number of markets that employ varying IRP and 
TRP rules will assist manufacturers in identifying an optimized price and launch 
sequence strategy.
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Objectives: Alzheimer’s dementia (AD) poses a significant challenge to health care 
systems around the world. Whilst treatment options are currently limited, with no 
effective disease modifying treatment, new advances in diagnosis and manage-
